- Plenary session on petosemtamab: October 24, 10:00-11:40 a.m. ET.
- Poster session on preclinical evaluation: October 24, 12:30-4:00 p.m. ET.
- Petosemtamab targets EGFR and LGR5 in cancer treatment.
- Abstracts available in conference app on October 22, 12:00 p.m. ET.
Conference Presentations
Merus will present data on petosemtamab at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025. A plenary session will feature interim data from a phase 2 trial of petosemtamab in metastatic colorectal cancer (mCRC) on October 24, from 10:00 to 11:40 a.m. ET. A poster session on the preclinical evaluation of petosemtamab on cancer stem cells will occur on the same day from 12:30 to 4:00 p.m. ET.
Petosemtamab Overview
Petosemtamab, also known as MCLA-158, is a Biclonics® antibody targeting EGFR and LGR5. It is designed to inhibit EGFR-dependent signaling, promote EGFR internalization and degradation, and enhance antibody-dependent cell-mediated cytotoxicity and phagocytosis.
Abstract Availability
The abstracts for the presentations will be accessible in the conference app starting October 22, 2025, at 12:00 p.m. ET. Full presentations will be available on the Merus website at the start of each session.
